13573 related articles for article (PubMed ID: 10379864)
1. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
[TBL] [Abstract][Full Text] [Related]
2. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
3. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
4. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
[TBL] [Abstract][Full Text] [Related]
5. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
6. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
Stam TC; Swaak AJ; de Vries MR; ten Hagen TL; Eggermont AM
Ann Surg Oncol; 2000 May; 7(4):268-75. PubMed ID: 10819366
[TBL] [Abstract][Full Text] [Related]
7. Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
Sonneveld EJ; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1996 Oct; 22(5):521-7. PubMed ID: 8903497
[TBL] [Abstract][Full Text] [Related]
8. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
[TBL] [Abstract][Full Text] [Related]
9. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
13. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
14. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
16. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
[TBL] [Abstract][Full Text] [Related]
17. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
19. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
